TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23816488

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention consisting of 3-4 short MI sessions and a maintenance phase delivered by trained researchers.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine advice (Control group)
Number of subjects: 0
Study: 21424238

Group type: EXPERIMENTAL
Intervention: Topical steroids (prednisolone 0.5%)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Lubricants
Number of subjects: 117

Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drops
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment duration
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 117
Study: 19894007

Group type: EXPERIMENTAL
Intervention: Pulsed signal therapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 95
Study: 17362810

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily for 7 days
Number of subjects: 575

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500/125 mg 3 times daily for 10 days
Number of subjects: 575
Study: 15279531

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Psychosocial Rehabilitation (PSR)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard Services
Number of subjects: 204
Study: 11210396

Group type: COMPARATOR
Intervention: NN703 (growth hormone secretagogue) administered po as a solution, dose levels: 8, with 6 subjects on active treatment per dose level.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (control group), 2 subjects per dose level.
Number of subjects: 48
Study: 9553909

Group type: EXPERIMENTAL
Intervention: Low-dose etretinate therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal skin from RTRs
Number of subjects: 15

Group type: COMPARATOR
Intervention: SCCs, BCCs, dysplastic lesions, and viral warts
Number of subjects: 15
Study: 7715058

Group type: EXPERIMENTAL
Intervention: General exercise
Number of subjects: 1323

Group type: EXPERIMENTAL
Intervention: Balance exercise
Number of subjects: 1323

Group type: COMPARATOR
Intervention: No exercise component
Number of subjects: 1323
Study: 2667615

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 18
Study: 359938

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 99

Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 99
Study: 31834814

Group type: EXPERIMENTAL
Intervention: Daily running exercise for 7 days
Number of subjects: 9
Study: 31379058

Group type: EXPERIMENTAL
Intervention: Tenofovir or adefovir treatment for 4 years
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Detection of HBsAg clearance profiles (CPs)
Number of subjects: 25
Study: 27851857

Group type: EXPERIMENTAL
Intervention: Eravacycline, 1.0 mg/kg every 12 hours for a minimum of four 24-hour dosing cycles
Number of subjects: 541

Group type: COMPARATOR
Intervention: Ertapenem, 1.0 g every 24 hours for a minimum of four 24-hour dosing cycles
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Eravacycline
Number of subjects: 541

Group type: COMPARATOR
Intervention: Ertapenem
Number of subjects: 541
Study: 25611803

Group type: EXPERIMENTAL
Intervention: Mometasone (400 μg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mometasone (400 μg) administered 30 min before albuterol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo administered 30 min before albuterol
Number of subjects: 15
Study: 25739188

Group type: EXPERIMENTAL
Intervention: Remaxol (intravenous drip, 400 ml per day, 10 days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Essentiale N (intravenous bolus, 5 ml per day, 10 days)
Number of subjects: 90
Study: 22621970

Group type: EXPERIMENTAL
Intervention: Lowest tertile of 1,25(OH)(2)D
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Lower tertiles of 1,25(OH)(2)D after adjustment for FGF-23
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations
Number of subjects: 1099
Study: 19533757

Group type: EXPERIMENTAL
Intervention: C-PDT (combined type I photorejuvenation with wrinkle reduction)
Number of subjects: 37

Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 37
Study: 17585221

Group type: EXPERIMENTAL
Intervention: 0.1 mg etanercept intradiscally
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.25 mg etanercept intradiscally
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.5 mg etanercept intradiscally
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.75 mg etanercept intradiscally
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.0 mg etanercept intradiscally
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.5 mg etanercept intradiscally
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15334011

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 60
Study: 11142672

Group type: EXPERIMENTAL
Intervention: Triclosan toothpaste
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control toothpaste (non‐triclosan, conventional fluoride toothpaste)
Number of subjects: 24
Study: 9704955

Group type: EXPERIMENTAL
Intervention: PolyHeme (up to 6 U, 300 g)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Allogeneic red blood cells (RBCs)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PolyHeme
Number of subjects: 44
Study: 8003843

Group type: EXPERIMENTAL
Intervention: Intermittent high-impact exercise (test group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low-impact exercise (control group)
Number of subjects: 27
Study: 2805891

Group type: EXPERIMENTAL
Intervention: Infants who played with both cans and tubes in their home for 1 month
Number of subjects: 50

Group type: COMPARATOR
Intervention: 14-month-olds (untrained)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 20-month-olds (untrained)
Number of subjects: 50
Study: 30408227

Group type: EXPERIMENTAL
Intervention: Associative group received 30 pairings of a peripheral electrical nerve stimulus (ES) during the most active phase of the motor cortex
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group received low intensity ES that did not stimulate the nerve
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Associative group
Number of subjects: 24
Study: 28449721

Group type: EXPERIMENTAL
Intervention: Complex intervention based on the implementation of the Ariadne principles with two components: (1) FP training and (2) FP‐patient interview.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Complex intervention based on the implementation of the Ariadne principles.
Number of subjects: 400
Study: 25738481

Group type: EXPERIMENTAL
Intervention: ACEI-based treatment (enalapril)
Number of subjects: 6083

Group type: COMPARATOR
Intervention: Diuretic-based treatment (hydrochlorothiazide)
Number of subjects: 6083
Study: 23175450

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study: 21198801

Group type: EXPERIMENTAL
Intervention: Changing the needle prior to administering diclofenac sodium intramuscularly
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard injection technique (not changing the needle)
Number of subjects: 100
Study: 18364323

Group type: EXPERIMENTAL
Intervention: Lactose-free formula with 10(9)CFU B. lactis Bb12 and 5x10(8)CFU St. thermophilus TH4 per gram of powder
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Lactose-free formula with 10(8)CFU B. lactis Bb12 and 5x10(7)CFU St. thermophilus TH4 per gram of powder
Number of subjects: 224

Group type: COMPARATOR
Intervention: Lactose-free formula (Control)
Number of subjects: 224
Study: 16433809

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% in thermophobic foam (CF) applied twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo applied twice daily
Number of subjects: 26
Study: 12769149

Group type: EXPERIMENTAL
Intervention: Menicon Z RGP contact lenses (tisilfocon A, Dk = 163) worn continuously for up to 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: ACUVUE hydrogel contact lenses (etafilcon A, Dk = 28) worn for up to 6 nights of extended wear
Number of subjects: 60
Study: 10757587

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100

Group type: COMPARATOR
Intervention: Desflurane and Sevoflurane
Number of subjects: 100
Study: 9051539

Group type: EXPERIMENTAL
Intervention: Oral-transdermal clonidine regimen (4 to 5 mu/kg oral clonidine and 0.2 mg/24 hours transdermal patch)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo tablet and patch
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Oral-transdermal clonidine regimen
Number of subjects: 29
Study: 7786992

Group type: EXPERIMENTAL
Intervention: Bias-corrected estimation of model parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated envelope approach
Number of subjects: 0
Study: 3354781

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 93

Group type: COMPARATOR
Intervention: Portacaval shunt
Number of subjects: 93
Study: 31587660

Group type: EXPERIMENTAL
Intervention: Peak systolic blood pressure (SBP) >158 mm Hg
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Peak systolic blood pressure (SBP) 158 mm Hg
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Peak systolic blood pressure (SBP) >158 mm Hg (adjusted analysis)
Number of subjects: 485
Study: 29151562

Group type: EXPERIMENTAL
Intervention: Sleep improvement program combined with aroma-necklace (marjoram and orange oil), 4 weeks, 1 hour per week
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 70
Study: 26447154

Group type: EXPERIMENTAL
Intervention: d6-RRR-α-tocopherol (15 mg) with nonfat milk (0.2 g fat)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: d6-RRR-α-tocopherol (15 mg) with reduced-fat milk (4.8 g fat)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: d6-RRR-α-tocopherol (15 mg) with whole milk (7.9 g fat)
Number of subjects: 20
Study: 23233252

Group type: EXPERIMENTAL
Intervention: Topical pazopanib 0.5% for 3 weeks
Number of subjects: 20
Study: 20054593

Group type: EXPERIMENTAL
Intervention: DFDBA + EMD
Number of subjects: 56

Group type: COMPARATOR
Intervention: DFDBA
Number of subjects: 56
Study: 18448276

Group type: EXPERIMENTAL
Intervention: General movements (GMs) observation at term
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: General movements (GMs) observation at three months
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mildly or definitely abnormal GMs at three months
Number of subjects: 175
Study: 16496249

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dorzolamide + Timolol Fixed Combination (DTFC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 50
Study: 14594782

Group type: EXPERIMENTAL
Intervention: Endosperm rye bread
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Traditional rye bread
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-fiber rye bread
Number of subjects: 19

Group type: COMPARATOR
Intervention: Refined wheat bread (control)
Number of subjects: 19
Study: 10699771

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with meperidine as additional analgesia, self-administered by patients.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard sedation with meperidine and midazolam administered by the anesthesiologist.
Number of subjects: 56
Study: 9577115

Group type: COMPARATOR
Intervention: Blue-green equation testing with the IF-2 All-Color Anomaloscope
Number of subjects: 52
Study: 8408793

Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate (MPA) 0.1% ointment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mometasone furoate ointment
Number of subjects: 20
Study: 2960897

Group type: EXPERIMENTAL
Intervention: t-PA (80 to 100 mg intravenously over three hours)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Angioplasty (performed on the third hospital day)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: t-PA
Number of subjects: 138
Study: 29906270

Group type: COMPARATOR
Intervention: Zirconia post
Number of subjects: 22

Group type: COMPARATOR
Intervention: Polyethylene fiber post
Number of subjects: 22
Study: 26684775

Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (DBS) of the fornix
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 42
Study: 25602175

Group type: EXPERIMENTAL
Intervention: Ranolazine 375 mg bid
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Ranolazine 500 mg bid
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Ranolazine 750 mg bid
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Combined ranolazine 500 mg and 750 mg
Number of subjects: 241
Study: 23969113

Group type: EXPERIMENTAL
Intervention: Fibrin Pad
Number of subjects: 100

Group type: COMPARATOR
Intervention: Absorbable hemostat
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fibrin Pad and Absorbable hemostat
Number of subjects: 100
Study: 20001868

Group type: EXPERIMENTAL
Intervention: Dienogest (DNG) 2 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal buserelin acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norethisterone acetate 10 mg/day
Number of subjects: 0
Study: 18360662

Group type: EXPERIMENTAL
Intervention: Implant anchorage
Number of subjects: 26

Group type: COMPARATOR
Intervention: Regular maximum anchorage
Number of subjects: 26
Study: 16893642

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventionally dosed chemotherapy (group A)
Number of subjects: 42
Study: 12897584

Group type: EXPERIMENTAL
Intervention: Episcleral venous pressure in the supine position for older subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Episcleral venous pressure in the supine position for younger subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intraocular pressure in the supine position for older subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intraocular pressure in the supine position for younger subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Increase in intraocular pressure in the supine position for younger subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Increase in intraocular pressure in the supine position for older subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Increase in episcleral venous pressure in younger subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Increase in episcleral venous pressure in older subjects
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Blood pressure in older subjects
Number of subjects: 2
Study: 10460994

Group type: EXPERIMENTAL
Intervention: 17alpha-hydroxyprogesterone caproate (17-OHPc) at a dosage of 341 mg every 3 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Saline solution as placebo every 3 days
Number of subjects: 86
Study: 9569872

Group type: EXPERIMENTAL
Intervention: Modified, all-metal, Extension Cone Paralleling (XCP-II) film holder
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional Extension Cone Paralleling (XCP-I) film holder
Number of subjects: 78
Study: 1799476

Group type: EXPERIMENTAL
Intervention: IFN + VMCP
Number of subjects: 89

Group type: COMPARATOR
Intervention: IFN
Number of subjects: 89
Study: 6349256

Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 32
Study: 31957794

Group type: EXPERIMENTAL
Intervention: Telephone outreach call plus invitation to engage in mental health tailored telephone counseling and assistance obtaining nicotine replacement therapy
Number of subjects: 982

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 982
Study: 31421395

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (136.6 mg aglycone equivalence)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 27287858

Group type: EXPERIMENTAL
Intervention: Outpatient THA (discharged on the same day)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Inpatient THA (discharged after an overnight stay)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Outpatient THA
Number of subjects: 220

Group type: COMPARATOR
Intervention: Inpatient THA
Number of subjects: 220
Study: 26590838

Group type: EXPERIMENTAL
Intervention: Web mode
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: IVRS mode
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Paper mode
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: BFI subscales
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Overall mode equivalence
Number of subjects: 170
Study: 24383513

Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 22608580

Group type: EXPERIMENTAL
Intervention: Left nostril group
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Right nostril group
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both nostril groups (patients with epistaxis)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both nostril groups (patients who passed the tube easily)
Number of subjects: 118
Study: 20566178

Group type: EXPERIMENTAL
Intervention: Topical treatment based on severity: OSDI (mild) = carboxymethylcelullose, OSDI (moderate) = hidroxypropylmethylcelullose, OSDI (severe) = polyethyleneglycol, OSDI (very severe) = polyethyleneglycol + cyclosporine A 0.05%.
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Topical treatment administered based on severity of symptoms.
Number of subjects: 144
Study: 17029771

Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal Saline (N/S)
Number of subjects: 90
Study: 15333615

Group type: EXPERIMENTAL
Intervention: Model predicting inspiratory flow and area profile based on nasal wall compliance.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry and posterior rhinomanometry used to determine initial geometric area and mechanical characteristics.
Number of subjects: 11
Study: 12028164

Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg once daily (n = 507)
Number of subjects: 1015

Group type: COMPARATOR
Intervention: placebo (n = 508)
Number of subjects: 1015
Study: 10215688

Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg combined with midazolam 0.05 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pethidine 1.0 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride 4.0 mg/kg (oral)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo capsules (oral)
Number of subjects: 30
Study: 8570775

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) at a daily oral dose of 0.5 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 0
Study: 2223424

Group type: EXPERIMENTAL
Intervention: 7.5 mg of zopiclone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 600 mg of carbamazepine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined treatment with zopiclone and carbamazepine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clinical test for drunkenness (CTD)
Number of subjects: 12
Study: 453259

Group type: EXPERIMENTAL
Intervention: Laminaria placed at the time of the abortifacient injection (Group II, N = 23)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Laminaria placed 4 hours prior to injection (Group III, N = 29)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No additional therapy (Group I, N = 28)
Number of subjects: 80
Study: 31838255

Group type: EXPERIMENTAL
Intervention: Intensive treatment (110 ≤ SBP < 130 mmHg)
Number of subjects: 8511

Group type: COMPARATOR
Intervention: Mild treatment (130 ≤ SBP < 150 mmHg)
Number of subjects: 8511
Study: 31734256

Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection (LLR)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Open liver resection (OLR)
Number of subjects: 21
Study: 28889840

Group type: EXPERIMENTAL
Intervention: Acupuncture at CV-12 (Zhongwan) for 30 minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo control at a point on the right side of the abdomen for 30 minutes
Number of subjects: 40
Study: 26175420

Group type: EXPERIMENTAL
Intervention: Antiosteoporotic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 23853555

Group type: EXPERIMENTAL
Intervention: Bright light exposure at 7,000‐10,000 lux for > 30 minutes for at least 10 days during 2 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no bright light exposure, wore sunglasses after work)
Number of subjects: 92
Study: 21834326

Group type: EXPERIMENTAL
Intervention: Positive task interdependence
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Positive resource interdependence
Number of subjects: 66

Group type: COMPARATOR
Intervention: Individualistic learning
Number of subjects: 66
Study: 19651564

Group type: EXPERIMENTAL
Intervention: Not on Tobacco (NOT)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Kickin' Butts
Number of subjects: 407
Study: 16881774

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for bipolar disorder (duration up to 28 months)
Number of subjects: 0
Study: 15162892

Group type: EXPERIMENTAL
Intervention: Statins (including fluvastatin)
Number of subjects: 49275

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 49275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49275